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ABSTRACT
The 2-year, randomized, double-blind, active-controlled fracture endpoint VERO study included postmenopausal women with
established osteoporosis, who had at least 2moderate or 1 severe baseline vertebral fractures (VFx), and bonemineral density (BMD)
T-score–1.5. Patients were treatedwith either s.c. daily teriparatide 20mg or oral weekly risedronate 35mg. As previously reported,
the risk of new VFx and clinical fractures (a composite of clinical VFx and nonvertebral fragility fractures [NVFFx]) was statistically
signiﬁcantly reduced with teriparatide comparedwith risedronate. Here we present the prospectively planned subgroup analyses of
fracture data across subgroups, which were predeﬁned by the following baseline characteristics: age, number and severity of
prevalent VFx, prevalent nonvertebral fractures (NVFx), glucocorticoid use, prior osteoporosis drugs, recent bisphosphonate use,
clinical VFx in the year before study entry, and baseline BMD. Heterogeneity of the treatment effect on the primary endpoint (new
VFx), and the four key secondary endpoints (including clinical fractures and NVFFx) were investigated by logistic and Cox
proportional hazards regression models. A total of 1360 women were randomized and treated (680 per group). Mean age was 72.1
years, mean (SD) number of prevalent VFx was 2.7 (2.1), 55.4% had a BMD T-score<–2.5, 36.5% had a recent clinical VFx, 28.3% had a
prior major NVFx, 43.2% were osteoporosis drug-na€ıve, 39.3% were recent bisphosphonate users, and 9.3% were taking
glucocorticoids at a prednisone-equivalent dose of >5mg/d. For most fracture endpoints, the risk reduction of teriparatide versus
risedronate did not signiﬁcantly differ in any of the subgroups analyzed (treatment-by-subgroup interaction p> 0.1), with most
subgroupsmirroring results from the total study population. In conclusion, in postmenopausal womenwith severe osteoporosis, the
antifracture efﬁcacy of teriparatide compared with risedronate was consistent in a wide range of patient settings, including
treatment-na€ıve and previously treated patients. © 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley
Periodicals Inc.
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Introduction
The choice of the drug treatment for secondary prevention offragility fractures in patients with osteoporosis is a
controversial topic. Most osteoporosis guidelines consider oral
bisphosphonates as a ﬁrst-line therapy, whereas other anti-
resorptives such as zoledronate or denosumab or the bone-
forming agent teriparatide are recommended as second-line
therapies. We have recently reported the “VERtebral fracture
treatment comparisons in Osteoporotic women” (VERO) trial,(1)
the ﬁrst active-controlled clinical trial adequately designed to
show superiority in the incidence of new vertebral fractures
(VFx) as the primary endpoint, comparing teriparatide with
risedronate, an oral bisphosphonate that has shown signiﬁcant
antifracture efﬁcacy results in postmenopausal women with low
bone mass and prevalent VFx.(2–5) In the VERO trial, 24-month
treatment with teriparatide signiﬁcantly reduced the incidence
of VFx and clinical fractures (a composite of clinical VFx and
nonvertebral fragility fractures [NVFFx]) compared with risedr-
onate by 56% and 52%, respectively, in postmenopausal women
with established osteoporosis.(1)
Several major risk factors for osteoporotic fractures are
recognized, including age, bone mineral density (BMD),
glucocorticoid use, or a prior fracture.(6–8) These factors may
inﬂuence the treatment effect of the anti-osteoporosis drugs.
Using the data from the VERO trial, we examined whether the
treatment effect on the incidence of new fractures observed in
the entire population as reported by Kendler and colleagues(1)
was heterogeneous across predeﬁned subgroups by clinically
relevant baseline characteristics. Similar subgroup analyses have
been reported previously for alendronate,(9) risedronate,(4)
zoledronic acid,(10) denosumab,(11) and abaloparatide(12) in the
population of patients enrolled in the phase 3 trials but using
placebo as the comparator, instead of an active comparator as
utilized in the present study.
Materials and Methods
Study design
In this double-blind, multinational, multicenter trial, post-
menopausal women with at least 2 moderate or 1 severe
VFx, according to the classiﬁcation of Genant and
colleagues,(13) and a BMD T-score of –1.5 were enrolled.
After their eligibility was conﬁrmed, 1360 women were
randomized to receive either 20mg of s.c. teriparatide once
daily plus oral weekly placebo (680 treated patients) or
35 mg of oral risedronate once weekly plus daily injections
of placebo (680 treated patients) for up to 24 months. The
primary study outcome was the incidence of new radio-
graphic VFx. A new VFx was deﬁned as a vertebral body
height loss of at least 20% (and 4mm) of a vertebra that was
unfractured at baseline, based on a 6-point placement of
the vertebral bodies from T4 to L4, and conﬁrmed by an
increase by one or more severity grades according to the
semiquantitative grading (SQ) scale by Genant and col-
leagues.(13) Key secondary outcomes included the incidence
of pooled new and worsened VFx, clinical fractures (a
composite of clinical VFx and NVFFx), NVFFx (excluding
pathologic fractures and fractures of the skull, face, ﬁngers,
metacarpals, and toes), and a subgroup of major NVFFx (hip,
radius, humerus, rib, pelvis, tibia, and femur) per the
European Medicines Agency deﬁnition.(14) Worsening of a
baseline preexisting spine fracture was diagnosed if the
decrease in vertebral height was at least one severity grade
in the SQ assessment. A clinical VFx was deﬁned as an
episode associated with signs and symptoms highly
suggestive of a VFx, such as severe back pain of acute
onset; pain with little or no exertion; pain localized to
speciﬁc vertebra and associated with limited back mobility;
pain relieved by bed rest; worsened when upright,
coughing, sneezing; limited back ﬂexion; or paravertebral
muscle tenderness secondary to spasms, conﬁrmed with the
detection of a new or worsened radiographic VFx by the
centralized X-ray imaging readers. Analyses of nonvertebral
and pooled clinical fractures were based on all randomized
patients who received at least 1 dose of investigational
product (full analysis set) and analyses of VFx on all patients
with a baseline and at least 1 post-baseline spinal
radiograph evaluable to assess the VFx status after
24 months (modiﬁed full analysis set). Further study design,
entry criteria, and methodology details are described by
Kendler and colleagues(1) in their article summarizing the
trial’s main efﬁcacy and safety results.
Subgroup analyses
Subgroup analyses were prospectively planned and performed
primarily to examine if the treatment effect differs across the
different predeﬁned subgroups and, therefore, consistent with
the results observed in the entire population. A second aim was
to explore the treatment effect within speciﬁc subgroups that
were considered to be clinically relevant and that have not
previously been reported in clinical trials. Subgroup analyses
were exploratory and were done for the primary and the key
secondary fracture endpoints as deﬁned in the statistical
analysis plan of the study that was approved before study
unblinding.(1) The following subgroups were prespeciﬁed and
analyzed: 1) by number of prevalent fragility VFx; 2) by severity
of prevalent VFx using the classiﬁcation by Genant and
colleagues;(13) 3) by prevalent major NVFx, where major NVFx
included fractures of the hip, radius, humerus, ribs, pelvis, tibia,
and femur (excluding pathologic fractures); 4) by use of
signiﬁcant glucocorticoid treatment, deﬁned as >5mg/d of
prednisone-equivalent dose at the baseline visit or during post-
baseline visits, regardless of treatment duration; 5) by prior use
of osteoporosis drugs using 3 different mutually exclusive
categories: prior bisphosphonates users, prior users of osteopo-
rosis medication other than a bisphosphonate, and osteoporosis
treatment-na€ıve patients. The category of prior bisphosphonate
users included those patients who had received 3 months of
oral (risedronate, alendronate, ibandronate, etidronate, neridr-
onate), i.m. (clodronate) or i.v. (ibandronate, pamidronate,
clodronate) bisphosphonates, or 1 dose of i.v. zoledronic acid.
The category of nonbisphosphonate users included those
patients who had received 3 months of any nonbisphosph-
onate antiresorptive (excepting denosumab) or 1 dose of s.c.
denosumab. Osteoporosis treatment-na€ıve patients included
patients who had not received any osteoporosis medication, or
<3months of the antiresorptive drugs listed above. Calcium and
vitamin D supplements were not considered osteoporosis
medications; 6) by the lowest baseline T-score (<–2.5 or
–2.5 SDs) measured at the spine and the proximal femur; 7)
by age categorized by tertiles; 8) by recent bisphosphonate use,
where recent use was deﬁned as a total of 6 or more months of
treatment with any oral bisphosphonate—either intermittently
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or continuously—within 3 years before screening, or i.v.
zoledronic acid at any dose within 2 years of screening, or i.v.
ibandronate or pamidronate at any dose within 12 months
before screening; and 9) by antecedent of recent clinical VFx
within 12 months before screening. Because 97.3% of the
patients in this study were white, analyses by the predeﬁned
ethnicity subgroups of whites versus non-whites were not
considered feasible.
Statistical analyses
Fracture endpoints in subgroups were analyzed following the
same prespeciﬁed statistical methods applied in the main
analysis of the VERO trial.(1) Cochran-Mantel-Haenszel tests,
adjusted for the two stratiﬁcation factors used at randomization
(ie, the antecedent of recent clinical VFx and recent
bisphosphonate use) were employed to estimate the overall
treatment effect between teriparatide and risedronate for the
primary and secondary analyses of the morphometric (radio-
graphic) VFx endpoints. For the subgroup analysis of the
morphometric (radiographic) VFx endpoints, a logistic regres-
sion analysis with the adjusting factors treatment, subgroup,
treatment-by-subgroup interaction, and the two stratiﬁcation
factors was ﬁtted. These analyses were implemented in the
modiﬁed full analysis set that included all randomized patients
who received1 dose of either investigational product andwho
had 1 post-baseline spine X-ray available to assess their
fracture status during 24 months.
Table 1. Number of Patients per Subgroup (Full Analysis Set and Modiﬁed Full Analysis Set)
No. (%) of patients
Full analysis set Modified full analysis set
Teriparatide (N¼ 680) Risedronate (N¼ 680) Teriparatide (N¼ 516) Risedronate (N¼ 533)
Prevalent VFx (number)a
1 231 (34.0) 240 (35.3) 180 (34.9) 191 (35.8)
2 178 (26.2) 174 (25.6) 132 (25.6) 135 (25.3)
3 104 (15.3) 101 (14.9) 86 (16.7) 82 (15.4)
>3 166 (24.4) 164 (24.1) 118 (22.9) 125 (23.5)
Prevalent VFx (severity)a
SQ2 73 (10.7) 67 (9.9) 59 (11.4) 57 (10.7)
SQ3 606 (89.1) 612 (90.0) 457 (88.6) 476 (89.3)
Prior major nonvertebral fractureb
No 481 (70.7) 494 (72.6) 355 (68.8) 385 (72.2)
Yes 199 (29.3) 186 (27.4) 161 (31.2) 148 (27.8)
Glucocorticoid usec
No 609 (89.6) 624 (91.8) 466 (90.3) 491 (92.1)
Yes 71 (10.4) 56 (8.2) 50 (9.7) 42 (7.9)
Prior osteoporosis drugsd
Bisphosphonate 359 (52.8) 356 (52.4) 280 (54.3) 281 (52.7)
Nonbisphosphonate 26 (3.8) 31 (4.6) 23 (4.5) 25 (4.7)
Treatment-na€ıve 295 (43.4) 293 (43.1) 213 (41.3) 227 (42.6)
Lowest BMD T-score
<–2.5 371 (54.6) 382 (56.2) 270 (52.3) 297 (55.7)
–2.5 309 (45.4) 298 (43.8) 246 (47.7) 236 (44.3)
Age, years (tertiles)
<68.7 years 217 (31.9) 236 (34.7) 184 (35.7) 202 (37.9)
68.7 and <76.8 years 213 (31.3) 241 (35.4) 152 (29.5) 192 (36.0)
76.8 years 250 (36.8) 203 (29.9) 180 (34.9) 139 (26.1)
Recent bisphosphonate use
No 414 (60.9) 412 (60.6) 309 (59.9) 324 (60.8)
Yes 266 (39.1) 268 (39.4) 207 (40.1) 209 (39.2)
Recent clinical VFx
No 428 (62.9) 436 (64.1) 319 (61.8) 341 (64.0)
Yes 252 (37.1) 244 (35.9) 197 (38.2) 192 (36.0)
VFx¼ vertebral fractures; SQ¼ semiquantitative grading; BMD¼bone mineral density.
Note: The full analysis set (FAS) included all randomized patients who received 1 dose of investigational product, and the modiﬁed full analysis set
included all FAS patients who had 1 post-baseline spine X-ray available to assess their fracture status during 24 months.
aExcept for 2 patients, all patients in the FAS had at least 1 vertebral fracture (according to the central assessment) at baseline as per entry criteria. For
these 2 patients, central fracture adjudication was not available, which was considered a major protocol violation.
bHip, radius, humerus, ribs, pelvis, tibia, and femur (excluding pathologic fractures).
cPrednisone-equivalent doses of >5mg/d at the baseline or any post-baseline visit.
dBisphosphonate: 3 months of bisphosphonates (ie, risedronate, alendronate, ibandronate, etidronate, neridronate, clodronate, or pamidronate) or
1 dose of i.v. zoledronic acid; nonbisphosphonate: 3 months of any nonbisphosphonate antiresorptive (except denosumab) or 1 dose of
denosumab; treatment-na€ıve: no osteoporosis medication or who received<3 months of the antiresorptive drugs listed above. Calcium and vitamin D
supplements were not considered osteoporosis medications.
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Stratiﬁed log-rank tests, adjusted for the two stratiﬁcation
factors, were employed for the analyses of the clinical fracture
endpoints (NVFx and clinical VFx). The overall hazard ratio to
estimate the treatment effect of teriparatide versus risedronate
was obtained as part of the stratiﬁed log-rank test calculations.
The corresponding subgroup analyses of the clinical fracture
endpoints were performed using a Cox proportional hazards
regression model with the same factors as speciﬁed above for
the logistic regression model. These analyses were conducted in
the full analysis set that included all randomized patients who
received 1 dose of either investigational product.
The relative risk ratios (for VFx) or the hazard ratios (for clinical
fractures) with the associated 95% CIs and p values for
teriparatide versus risedronate at each level of the subgroup
factor and overall were presented in forest plots, together with
the incidence rates per treatment group within subgroup and
the treatment-by-subgroup interaction p value. A treatment-by-
subgroup interaction p value <0.1 was considered as evidence
for the corresponding subgroup acting as an effect modiﬁer, ie,
the treatment effect of teriparatide versus risedronate would
differ depending on the category of the subgroup.
Results
Baseline characteristics
A total of 1360 patients were randomized and treated, 680 in
each treatment group; 74.2% of patients overall completed the
trial. Baseline demographics and clinical characteristics were
similar between groups and have been described previously in
Fig. 1. Relative risk ratio for new vertebral fractures by prespeciﬁed subgroups (modiﬁed full analysis set). BP¼bisphosphonates; N¼ total number of
patients; n¼number of patients in the speciﬁed category; SQ¼ semiquantitative grading; VFx¼ vertebral fracture. Major nonvertebral fractures: hip,
radius, humerus, ribs, pelvis, tibia, and femur (excluding pathologic fractures). Nonbisphosphonates include strontium ranelate, denosumab,
calcitonin, ﬂuoride, and vitamin D active metabolites.
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detail by Kendler and colleagues.(1) The numbers of patients per
subgroup were balanced between treatment groups in the two
analyzed data sets (Table 1). The overall mean agewas 72.1 years
and 97.3% of patients were white. The mean (SD) number of
prevalent VFx was 2.7 (2.1), with 1218 patients (89.6%) having
1 severe (SQ3) VFx at baseline. In the full analysis set, 496
patients (36.5%) had a clinical VFx within the 12 months before
entering the study, 385 (28.3%) had a prior major NVFx, and 753
(55.4%) had a lowest BMD T-score of <–2.5 (Table 1).
Furthermore, 588 patients (43.2%) were na€ıve to osteoporosis
medication, 534 (39.3%) had been recently treated with
bisphosphonates (as per protocol deﬁnition), and 127 patients
(9.3%) were taking glucocorticoids at a prednisone-equivalent
dose of >5mg/d.
Subgroup analysis results for new vertebral fractures
The forest plot in Fig. 1 illustrates the relative risk ratios between
teriparatide and risedronate for the incidence of new VFx, the
primary study endpoint, at 24 months within each subgroup as
well as overall. The treatment effect found in the entire study
population, with an incident rate of new VFx of 5.4% in the
teriparatidegroup comparedwith 12.0% in the risedronate group
(risk ratio 0.44; 95% conﬁdence interval [CI] 0.29–0.68;
p¼ 0.000094 [Fig. 1; see Kendler and colleagues(1) for details]),
was homogeneous across all subgroups, ie, the treatment-by-
subgroup interactions were not statistically signiﬁcant (p 0.1)
for any of the subgroups. Although none of the subgroups
analyzed acted as an effect modiﬁer, the signiﬁcant treatment
Fig. 2. Relative risk ratio for pooled new and worsened vertebral fractures by prespeciﬁed subgroups (modiﬁed full analysis set). BP¼bisphosphonates;
N¼ total number of patients; n¼number of patients in the speciﬁed category; SQ¼ semiquantitative grading; VFx¼ vertebral fractures. Major
nonvertebral fractures: hip, radius, humerus, ribs, pelvis, tibia, and femur (excluding pathologic fractures). Nonbisphosphonates include strontium
ranelate, denosumab, calcitonin, ﬂuoride, and vitamin D active metabolites.
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effect in favor of teriparatide found in the entire population was
numerically greater in the subgroups of patients with 2 prevalent
VFx (risk ratio 0.28; 95% CI 0.09–0.81), patients with a prior major
NVFx (risk ratio 0.27; 95% CI 0.13–0.58), the oldest patient group
(aged76.8 years) (risk ratio 0.33; 95% CI 0.15–0.73), and patients
with a recent clinical VFx within the 12 months before entering
the study (risk ratio 0.35; 95% CI 0.20–0.62) (Fig. 1). Of note, the
recent use of bisphosphonates did not inﬂuence the overall
efﬁcacy results with an almost identical, statistically signiﬁcant,
relative fracture risk reduction inpatientswith (risk ratio 0.46; 95%
CI 0.24–0.88) or without (risk ratio 0.42; 95% CI 0.24–0.74) recent
bisphosphonate use (treatment-by-subgroup p¼ 0.85) (Fig. 1).
The relative VFx risk reduction was also very similar and
statistically signiﬁcant in the patients with <–2.5 or –2.5 of
the lowest BMD T-score value (risk ratio 0.43 and 0.47,
respectively, treatment-by-subgroup p¼ 0.86) (Fig. 1).
Subgroup analysis results for pooled new and worsened
vertebral fractures
As illustrated in the forest plot for the incidenceof pooled newand
worsened VFx (Fig. 2), the treatment effect found overall (risk ratio
0.46; 95%CI 0.30–0.68;p¼ 0.000075 [seeKendler and colleagues(1)
for details]) was homogeneous across subgroups, with all but two
treatment-by-subgroup interactions not being statistically signiﬁ-
cant (p 0.1). Statistically signiﬁcant treatment-by-subgroup
interactions were observed for the subgroups by prior major
NVFx and by recent clinical fragility VFx (treatment-by-subgroup
Fig. 3. Hazard ratio for pooled clinical fractures (clinical vertebral and nonvertebral fragility fractures) by prespeciﬁed subgroups (full analysis set).
BP¼bisphosphonates; N¼ total number of patients; n¼number of patients in the speciﬁed category; SQ¼ semiquantitative grading; VFx¼ vertebral
fractures. Percentages indicate the cumulative incidence of fractures based on Kaplan-Meier methodology. Major nonvertebral fractures: hip, radius,
humerus, ribs, pelvis, tibia, and femur (excluding pathologic fractures). Nonbisphosphonates include strontium ranelate, denosumab, calcitonin,
ﬂuoride, and vitamin D active metabolites.
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p¼ 0.08 each). The risk ratio within the group of patients with a
priormajorNVFxwas0.26 (95%CI0.13–0.56),whereas in thegroup
ofpatientswithoutpriormajorNVFx, itwas0.57 (95%CI0.35–0.92),
suggesting a statistically larger reduction in new and worsened
VFx incidence for teriparatide in patients with a prior NVFx.
Similarly, within patients with a recent clinical fragility VFx, the risk
ratio was 0.32 (95% CI 0.18–0.57), whereas in patients without a
recent fragility VFx, it was 0.67 (95% CI 0.37–1.21).
Subgroup analysis results for pooled clinical fractures
(clinical vertebral and nonvertebral fragility fractures)
The overall treatment effect for the occurrence of new clinical
fractures was statistically in favor of teriparatide with a
cumulative incidence of 4.8% in the teriparatide group
compared with 9.8% in the risedronate group, corresponding
to a hazard ratio between teriparatide and risedronate of 0.48
(95% CI 0.32–0.74; p¼ 0.000869 [Fig. 3; see Kendler and
colleagues(1) for details]). The treatment effect in favor of
teriparatide was homogeneous across subgroups. The treat-
ment-by-subgroup interaction was not statistically signiﬁcant
(p 0.1) for any of the subgroups. Treatment effects within
subgroups showed similar patterns as described above for the
primary and ﬁrst key secondary endpoints, with numerically
greater treatment effects in favor of teriparatide observed for
patientswith 2 (hazard ratio 0.32; 95%CI 0.12–0.88) ormore than
3 prevalent VFx (hazard ratio: 0.33; 95% CI 0.14, 0.77), and
patients with recent clinical VFx (hazard ratio 0.38; 95% CI 0.20–
0.75) (Fig. 3). The reduction in the risk of clinical fractures was
statistically signiﬁcant and very similar to the overall population
in those patients who had received bisphosphonates as prior
osteoporosis drugs (hazard ratio 0.48; 95% CI 0.26–0.88) or had a
BMD T-score <–2.5 (hazard ratio 0.52; 95% CI 0.29–0.93). Fig. 4
shows the Kaplan-Maier curves of the cumulative incidence of
clinical fractures observed within the groups of osteoporosis
treatment-na€ıve patients and prior bisphosphonate users.
Subgroup analysis results for nonvertebral fragility
fractures
As illustrated in Fig. 5 for the VERO study population, the
overall estimate of the hazard ratio for the incidence of NVFFx
at 24 months between teriparatide and risedronate was 0.66
(95% CI 0.39–1.10; p¼ 0.0990 [Fig. 5; see Kendler and
colleagues(1) for details]). The treatment-by-subgroup inter-
actions were not statistically signiﬁcant (p 0.1) for any of the
subgroups analyzed. In all subgroups, the treatment difference
was not statistically signiﬁcant. The point estimates of the
hazard ratios of all the analyzed subgroups were very similar to
the overall estimate of the hazard ratio and numerically in
favor of teriparatide, with the exception of the patients with 1
prevalent VFx (hazard ratio 1.06; 95% CI 0.49–2.29) (Fig. 5). We
did not observe any increase in the risk of NVFFx fractures in
patients with antecedent of prior bisphosphonate use,
Fig. 4. Cumulative incidence of the ﬁrst clinical fracture (pooled clinical vertebral and nonvertebral fragility fractures) by prior use of osteoporosis drugs
(full analysis set). Hazard ratios for treatment-na€ıve patients and prior bisphosphonate users were both in favor of teriparatide.
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including those with recent bisphosphonate treatment. On the
contrary, the statistically nonsigniﬁcant risk reduction in the
prior bisphosphonate-treated patients was numerically similar
to that in the bisphosphonate-na€ıve group (Figs. 5 and 6A).
Subgroup analysis results for major nonvertebral fragility
fractures
Similar to the results for all NVFFx, albeit numerically in favor of
teriparatide, no statistically signiﬁcant between-treatment
difference for the incidence of major NVFFx was found (hazard
ratio 0.58; 95% CI 0.32–1.05; p¼ 0.0624 [Fig. 7; see Kendler and
colleagues(1) for details]). This nonsigniﬁcant treatment effect
was homogeneous across subgroups. All treatment-by-sub-
group interactions were not statistically signiﬁcant (p 0.1).
Among prior bisphosphonate-treated patients, the statistically
nonsigniﬁcant risk reduction was numerically similar to that in
the bisphosphonate-na€ıve group (Figs. 6B and 7).
Discussion
Our ﬁndings show that the overall treatment effects of
teriparatide on the reduction of VFx and clinical fractures that
were observed in the entire population of the VERO clinical trial
were also consistently observed across all prespeciﬁed sub-
groups analyzed. The treatment-by-subgroup interaction terms
were mostly not statistically signiﬁcant (p 0.1), indicating lack
of evidence in the data to conclude that the treatment effect was
heterogeneous across the different categories of the subgroups.
Fig. 5. Hazard ratio for nonvertebral fragility fractures by prespeciﬁed subgroups (full analysis set). BP¼bisphosphonates; N¼ total number of patients;
n¼number of patients in the speciﬁed category; SQ¼ semiquantitative grading; VFx¼ vertebral fractures. Percentages indicate the cumulative
incidence of fractures based on Kaplan-Meier methodology. Major nonvertebral fractures: hip, radius, humerus, ribs, pelvis, tibia, and femur (excluding
pathologic fractures). Nonbisphosphonates include strontium ranelate, denosumab, calcitonin, ﬂuoride, and vitamin D active metabolites.
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These results support and complement the subgroup analyses
by baseline BMD, age, and number of prevalent VFx performed
in the patient cohort included in a pivotal phase 3 placebo-
controlled clinical trial,(15) where no interactions were observed.
Subgroup analyses of large clinical trials are useful because
the beneﬁcial treatment effects of osteoporosis drugs may vary
across different categories of relevant risk factors, as has been
found before in clinical trials with hip fracture as the study
endpoint in patients treated with risedronate(5) or strontium
ranelate.(16) For instance, there is a lack of previous data from
randomized clinical trials on fracture outcomes in patients
receiving teriparatide who were pretreated with bisphospho-
nates. Earlier studies analyzing the effects of switching from
long-term treatment with a bisphosphonate to teriparatide on
BMD and biochemical markers of bone turnover have suggested
a “blunted” or “delayed” effect of subsequent teriparatide, at
least during the early treatment period.(17–20) Most recently, the
STRUCTURE study randomized patients previously on long-term
alendronate to either teriparatide or romosozumab, a monoclo-
nal antibody against sclerostin. At 12 months, both total hip
BMD and estimated hip strength signiﬁcantly increased with
romosozumab but declined with teriparatide, although no
differences in fracture outcomes, analyzed as adverse events,
between the two treatment groups were detected.(21) Our
subgroup data show similar antifracture efﬁcacy with teripara-
tide in bisphosphonate pretreated and treatment-na€ıve pa-
tients, even in those patients with recent bisphosphonate
treatment. This suggests that the antifracture efﬁcacy may differ
from thatwhich the bone strength surrogate endpoints indicate,
especially with agents differing inmechanism of action, and that
the observed early decrease in BMD in cortical-rich bones, such
as the forearm and the hip in patients switching to teriparatide
from antiresorptives, does not seem to be associated with an
increased risk of any type of fracture, including NVFx. These
ﬁndings are of clinical importance because they are obtained
from an active-controlled trial with risedronate, a bisphospho-
nate that has shown signiﬁcant reduction in NVFx and hip
fractures in two clinical trials that have analyzed patients with
established osteoporosis at high risk of fracture, similar to the
patients enrolled in the VERO study.(2,5) As long as a direct
comparison of fracture risk is not available between romoso-
zumab and teriparatide after bisphosphonate use, it remains
speculative whether the differences in changes in hip BMD and
calculated bone strength between these two drugs as reported
in the STRUCTURE study(21) reﬂect differences in fracture risk
during the early treatment after switching from bisphospho-
nates. On the other hand, the recently reported phase 3 trial of
abaloparatide, a parathyroid hormone-related protein analog, in
postmenopausal women with osteoporosis excluded patients
on previous recent antiresorptive therapy;(22) thus, no con-
clusions on the fracture efﬁcacy of abaloparatide in the clinical
setting of prior bisphosphonate use can be drawn from this
study.
Of particular importance is the residual burden of fracture risk
in patients on risedronate in the VERO study. Thus, 12% of the
patients treated with risedronate had a new VFx during the
24 months of follow-up and 9.8% a new clinical fracture. We
have demonstrated that teriparatide can effectively reduce this
residual fracture burden in these severely osteoporotic patients,
with an absolute risk reduction in new VFx of 6.6% after
24 months of treatment and a consistent effect over the wide
range of subgroups analyzed. These results conﬁrm previous
ﬁndings from two double-dummy, active-controlled trials that
included the comparison of the fracture incidence between
groups as secondary or exploratory endpoints. Thus, Hadji and
colleagues showed a signiﬁcant 5.0% absolute risk reduction in
new VFx with teriparatide compared with risedronate in a
randomized, double-blind, 18-month duration clinical trial in
Fig. 6. Cumulative incidence of the ﬁrst nonvertebral fragility fractures (A) and major nonvertebral fragility fractures (B) in prior bisphosphonate users
(full analysis set). NVFFx¼nonvertebral fragility fracture. aHip, radius, humerus, ribs, pelvis, tibia, and femur (excluding pathologic fractures).
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postmenopausal women with back pain and spine fractures.(23)
In the study reported by Saag and colleagues, patients with
glucocorticoid-induced osteoporosis treated with teriparatide
had an absolute risk reduction of 5.5% in VFx compared with
alendronate after the same treatment duration.(24)
The VERO study also provides new information about
antifracture efﬁcacy in patients with near-term fracture risk (or
imminent fracture risk) who are at the highest risk of subsequent
fractures (ie, the patients with a prior clinical VFx in the year
before entering the study). According to our results, the near-
term 2-year new VFx, new and worsened VFx, and clinical
fracture risks in these patients were still high in the risedronate-
treated group, but the fracture risks were signiﬁcantly reduced
with teriparatide by 65%, 68%, and 62% for new VFx, new and
worsened VFx, and clinical fractures, respectively (Figs. 1–3). The
reduction of NVFx remained not statistically signiﬁcant in this
subgroup (hazard ratio 0.60; 95% CI 0.28–1.27).
Also of special clinical and pharmacoeconomic interest is the
ﬁnding that teriparatide was superior to risedronate in the
reduction of clinical fractures, regardless of history of a prevalent
major NVFx, with a relative risk reduction of 57% after 24months
of treatment in patients with a prior NVFx. This risk reduction in
the VERO trial is similar to the 55% reduction in clinical fractures
observed in the 3-year Fracture Intervention Trial (FIT) I trial,
where alendronate was compared with placebo in a study
cohort with similar clinical characteristics, including the
presence of baseline VFx.(25) In the preplanned subgroup
analyses of the phase 3 denosumab and abaloparatide trials, no
Fig. 7. Hazard ratio for major nonvertebral fragility fractures by prespeciﬁed subgroups (full analysis set). BP¼bisphosphonates; N¼ total number of
patients; n¼number of patients in the speciﬁed category; SQ¼ semiquantitative grading; VFx¼ vertebral fractures. Percentages indicate the cumulative
incidence of fractures based on Kaplan-Meier methodology. Major nonvertebral fractures: hip, radius, humerus, ribs, pelvis, tibia, and femur (excluding
pathologic fractures). Nonbisphosphonates include strontium ranelate, denosumab, calcitonin, ﬂuoride, and vitamin D active metabolites.
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signiﬁcant antifracture effects of those two drugs on NVFx in
patients with a history of this type of fracture were found.(11,12)
The analysis by baseline NVFx was not considered in the
zoledronic acid subgroup analysis.(10) Clinical fractures were
analyzed as secondary fracture endpoints in the zoledronic acid
and abaloparatide phase 3 trials,(22,26) but they were not
reported in the subgroup analyses.(10,12)
Our presented analysis has several limitations common to
other subgroup study reports, including the limited power to
detect interactions. The VERO study was primarily designed to
detect a treatment effect difference between teriparatide and
risedronate for the primary endpoint of new VFx, and therefore
the detection of treatment-by-subgroup interactions would
have required a signiﬁcantly larger sample size. As a conse-
quence, the possibility of a true differential treatment effect for
some of the subgroups cannot be fully ruled out because of the
inherent lack of power of the study to detect such effect in
statistical tests. Additionally, some subgroups included very few
patients, such as the glucocorticoid users (less than 10% of the
entire population) or the prior nonbisphosphonate users (less
than 5% of the entire population), or had very few fracture
events. As a result, the CIs for the treatment effect estimated in
these subgroups are considerably wider than the corresponding
CI estimated using the overall population. Finally, the statistical
signiﬁcance was considered without adjustment for multiple
comparisons. As another limitation, surrogate markers of bone
quality such as BMD and biochemical markers of bone turnover
were not measured as study endpoints.
The strengths of the study include the enrollment of patients
with a high fracture risk, normally considered for osteoanabolic
therapy, and numerous clinically relevant prespeciﬁed sub-
groups—including prior osteoporosis therapy, a recent clinical
VFx, and number and severity of VFx at baseline—that have not
previously been analyzed in subgroup analyses and that
increase the clinical relevance to many patients that may be
candidates for bone anabolic therapy. This is the ﬁrst
randomized clinical trial that assesses fractures as efﬁcacy
endpoints in a substantial subgroup of patients pretreated with
bisphosphonates. We also included the analysis of relevant
clinical outcomes, such as clinical fractures, that have not been
reported before in subgroup analyses.
In conclusion, in postmenopausal women with severe
osteoporosis, the antifracture efﬁcacy of teriparatide compared
with risedronate was consistent within the various predeﬁned
subgroups. There was no evidence of heterogeneity in
treatment effect across the different categories of the subgroups
in reducing the risk of new VFx or clinical fractures. Teriparatide
antifracture efﬁcacy is similarly superior to risedronate in both
osteoporosis treatment-na€ıve and prior bisphosphonate-treated
patients. Data for the ﬁrst time indicate the additional fracture
beneﬁt of using an anabolic compared with an antiresorptive
across multiple patient clinical scenarios. This information
should aid in positioning teriparatide bone anabolic therapy
for reduction of residual fracture burden in patients at high
fracture risk who are either treatment-na€ıve or on bisphosph-
onate treatment.
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